期刊文献+

我国15岁及以上注射吸毒HIV感染者确证后的生存分析 被引量:4

Survival analysis since diagnosis of HIV-positive injecting drug users aged 15 years and above in China
原文传递
导出
摘要 目的了解我国报告注射吸毒HIV感染者的死亡情况及危险因素,为制定相关防治策略提供依据。方法资料来源于艾滋病综合防治信息系统注射吸毒HIV感染者,采用回顾性队列研究方法进行分析,计算死亡密度,并采用Cox比例风险回归模型分析死亡的风险因素,采用Excel 2019和SPSS 22.0软件进行数据整理和统计学分析。结果2001-2020年,我国累计报告≥15岁注射吸毒HIV感染者119209例,其中死亡59094例,全死因死亡密度为6.96/100人年,艾滋病相关死亡密度为1.91/100人年,总死亡密度呈下降趋势。多因素Cox比例风险回归模型分析结果显示,注射吸毒HIV感染者全死因死亡风险,相比于首次CD4+T淋巴细胞(CD4)计数>500个/µl者,未检测CD4计数、0~、200~和350~个/µl的HR值(95%CI)分别为2.85(2.78~2.93)、2.47(2.40~2.54)、1.58(1.53~1.62)和1.24(1.21~1.28);相比于抗病毒治疗者,未抗病毒治疗者的HR值(95%CI)为7.13(6.99~7.27);相比于美沙酮维持治疗者,未美沙酮维持治疗者的HR值(95%CI)为1.07(1.04~1.10)。注射吸毒HIV感染者艾滋病相关死亡风险,相比于首次CD4计数>500个/µl者,未检测CD4计数、0~、200~和350~个/µl的HR值(95%CI)分别为3.26(3.08~3.46)、5.54(5.24~5.85)、2.35(2.21~2.50)和1.41(1.32~1.50);相比于抗病毒治疗者,未抗病毒治疗者的HR值(95%CI)为5.96(5.74~6.18)。结论应促进注射吸毒人群HIV感染者的早诊断和早治疗,坚持参加美沙酮维持治疗等降低危害项目,提高其依从性,进而降低其死亡风险。 Objective To understand death's mortality and risk factors among HIV-positive injecting drug users(IDU)aged 15 or above in China and provide further reference to future prevention and treatment policies.Method Retrospective cohort study was conducted to calculate the mortality rate of HIV-positive IDU based on HIV/AIDS Comprehensive Response Information Management System.Cox proportion hazards regression model was performed to assess the risk factors for deaths.The Excel 2019 and SPSS 22.0 software was used for data cleaning and statistical analysis.Results Between 2001 and 2020,119209 HIV-positive IDU were reported with 59094 deaths.The all-cause mortality rate was 6.96 per 100 person-years(py),and the AIDS-related mortality rate was 1.91 per 100 py,with a decreasing trend over the years.Multivariate Cox regression indicated for all-cause death risks of HIV-positive IDU,compared with those baseline T+lymphocyte cells(CD4)counts above 500 cells/μl,the HR(95%CI)of those CD4 counts untested,between 0-199,200-349,350-500 cells/μl was 2.85(2.78-2.93),2.47(2.40-2.54),1.58(1.53-1.62)and 1.24(1.21-1.28)respectively.The HR(95%CI)of antiretroviral treatment(ART)naïve was 7.13(6.99-7.27)compared with those under ART.The HR(95%CI)of methadone maintenance treatment(MMT)naïve was 1.07(1.04-1.10)compared to those receiving MMT.As for AIDS-related death risks,compared with baseline T+lymphocyte cell CD4 counts>500 cells/μl,the HR(95%CI)of those CD4 counts untested,between 0-199,200-349,350-500 cells/μl was 3.26(3.08-3.46),5.54(5.24-5.85),2.35(2.21-2.50)and 1.41(1.32-1.50).HR(95%CI)of ART naïve was 5.96(5.74-6.18)compared to those under ART.Conclusions Further efforts should be made timely on diagnosis,treatment,and harm reduction programs such as MMT for improvement compliance to reduce mortality risks of HIV-positive IDU.
作者 金怡晨 蔡畅 陈方方 秦倩倩 汤后林 Jin Yichen;Cai Chang;Chen Fangfang;Qin Qianqian;Tang Houlin(Division of Epidemiology,National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2022年第6期860-864,共5页 Chinese Journal of Epidemiology
关键词 艾滋病病毒/艾滋病 注射吸毒 死亡 危险因素 HIV/AIDS Inject drug use Mortality Risk factors
  • 相关文献

参考文献7

二级参考文献36

  • 1曾毅 王必珠 郑锡文.艾滋病的血清流行病学调查研究.中华流行病学杂志,1988,9(3):138-138.
  • 2马瑛,李祖正,张开祥,等.首次在我国吸毒人群中发现艾滋病毒感染者[J].中华流行病学杂志,1990,11(3):184-185.
  • 3Wu ZY,Liu ZY,Detels R. HIV-1 infection in commercial plasma donors in China [J]. Lancet,1995,346(8966):61-62.
  • 4Wu ZY,Rou KM,Detels R. Prevalence of HIV infection among former commercial plasma donors in rural eastern China[J]. Health Policy Plan,2001,16(1):41-46.
  • 5Nerurkar VR,Wu ZY,Dashwood WM,et al. Complete nef gene sequence of HIV type 1 subtype B' from professional plasma donors in the People's Republic of China[J]. AIDS Res Hum Retroviruses,1998,14(5):461-464.
  • 6Wu ZY,Xu J,Liu EW,et al. HIV and syphilis prevalence among men who have sex with men:across-sectional survey of 61 cities in China[J]. Clin Infect Dis,2013,57(2):298-309.
  • 7National Center for AIDS/STD Control and Prevention,China CDC. National annual report on statistics of epidemics and prevention and treatment of HIV/AIDS,STD and hepatitis C in China in 2014 [R]. Beijing:2014. (in Chinese) 中国疾病预防控制中心性病艾滋病预防控制中心. 全国艾滋病/性病综合防治数据信息年报(2014)[R]. 北京:2014.
  • 8Sun XH,Wang N,Li DM,et al. The development of HIV/AIDS surveillance in China[J]. AIDS 2007,21 Suppl 8:S33-38.
  • 9中国疾病预防控制中心性病艾滋病预防控制中心. 2015年全国艾滋病/梅毒/丙肝哨点监测报告[R]. 北京:2015.
  • 10Liu YF,Wu ZY,Mao YR,et al. Quantitatively monitoring AIDS policy implementation in China. Int J Epidemiol,2010,39(Suppl 2):ii90-96.

共引文献241

同被引文献61

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部